06:04 PM EDT, 05/09/2024 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) reported a Q1 net loss late Thursday of $0.39 per diluted share, widening from a loss of $0.34 a year earlier.

Analysts polled by Capital IQ expected a loss per share of $0.42.

Revenue for the quarter ended March 31 was $13.8 million, up from $12.1 million a year earlier.

Analysts surveyed by Capital IQ expected $12.7 million.

The company had cash and cash equivalent of $296.3 million as of March 31.

Price: 8.70, Change: +0.06, Percent Change: +0.69